The use of platelet glycoprotein (GP) IIb-IIIa receptor inhibitors for reducing major thrombotic complications during percutaneous coronary intervention (PCI) has become common. Of the three agents, eptifibatide is approved for use in PCI and non-ST-segment elevation myocardial infarction (NSTEMI) patients, whereas abciximab is indicated for patients undergoing PCI (1). These agents inhibit platelet function by engaging the GPIIb-IIIa receptor and blocking the binding of the primary ligand fibrinogen to activated platelets (2). Previous studies have shown that the current abciximab dosing regimen achieves > 80% platelet receptor occupancy, with resultant effective platelet inhibition (3). Eptifibatide at 180 µg/kg bolus, plus 2.0 µg/kg/min infusion, has been shown to achieve similar results (4,5). Despite the proven benefit of GPIIb-IIIa inhibitors during PCI, significant interindividual variability exists in the level of platelet inhibition achieved with the recommended dosing regimens for these drugs (6,7) . Furthermore, a diminished degree of platelet inhibition is an independent predictor of adverse cardiac events (8).
Summary:
In 29 patients undergoing percutaneous coronary intervention (PCI), we obtained blood samples at baseline, 10 minutes after standard weight-based abciximab (n=15) or double-bolus eptifibatide (n=14) and 5 minutes after unfractionated heparin (UFH; 70 U/kg bolus). The median percent inhibition was significantly higher in the eptifibatide group compared with the abciximab group both before ( ing the effect of GP IIb-IIIa inhibitors. Comedication of unfractionated heparin (UFH) with GP IIb-IIIa inhibitors has been demonstrated to attenuate platelet inhibition in a few studies (11, 12) . It is possible that UFH may differentially affect the degree of platelet inhibition achieved by different GP IIb-IIIa inhibitors in patients undergoing PCIs. Accordingly, we have studied the effect of UFH on platelet inhibition induced by the most commonly administered inhibitors, eptifibatide and abciximab.
MATERIALS AND METHODS

Study Population
Blood samples were collected from 29 consecutive patients with stable angina who were undergoing elective, nonurgent coronary angioplasty with or without stent implantation. Aspirin (325 mg) was administered in all patients within the 24 hours preceding the study. Patients undergoing planned stent procedures received 300 mg of clopidogrel at least 6 hours before PCI. Study subjects were analyzed according to the GPIIb-IIIa inhibitor used, with 2 treatment groups for each: abciximab and abciximab + UFH, n=15; eptifibatide and eptifibatide+UFH, n=14. The selection of the GPIIb-IIIa inhibitor was at the operator's discretion. All studies were performed with the subject's written informed consent and conducted with the approval of the Committee on the Protection of the Rights of Human Subjects at the University of North Carolina.
Blood Samples
All blood samples were collected from the femoral arterial sheath, with baseline samples collected immediately after insertion. The first 5 mL were discarded, after which samples were collected for analysis from indwelling catheters. Using the same technique, two more blood samples were obtained. The second blood sample was obtained 10 minutes after administration of standard weight-based abciximab (0.25 mg/kg bolus + 0.125 µg/kg/min infusions) or doublebolus eptifibatide (180 µg/kg bolus × 2 [10 minutes apart] + 2 µg/kg/min infusion). After collecting the second sample, all patients received UFH (70 U/kg bolus). A third sample was obtained 5 minutes after administration of UFH.
Blood Sample Analysis
The activated clotting test (ACT) testing was performed with a Hemochron coagulation moni-tor (International Technidyne Corp.) using highrange tubes (FTCA 510) and reported in seconds. The upper limit of normal for ACT from this device in our laboratory is 150 seconds. The device used underwent daily calibration and quality testing. Activated partial thromboplastin time (aPTT) testing was performed in the hospital laboratory on blood anticoagulated with 3.2% citrate and reported in seconds. The mean normal values from the hospital laboratory were a 28.0 ± 2.5 seconds with an upper limit of normal of 33.0 seconds.
Platelet Aggregation
Samples for aggregometry were transferred to 5-mL polypropylene tubes and then spun at 150 g for 15 minutes. Platelet rich plasma then was transferred to new 5-mL polypropylene tubes. Platelet rich plasma aggregation on citrated blood was then performed with a PACKS-4 aggregometer (Helena Laboratories, Beaumont, TX) per the manufacturer's instructions. Adenosine diphosphate (ADP) and thrombin receptor agonist peptide (TRAP) in final concentrations of 20 and 15 µmol/L, respectively, were used as agonists for platelet aggregation (results reported in ohms). Baseline aggregations were monitored for 1 minute before the addition of agonists to ensure the absence of autoaggregation. Aggregations were then monitored for 4 minutes after the addition of agonists. Percent inhibition of aggregation was calculated by the equation: (baseline sample)/baseline) ×100. The aggregometer underwent daily calibration and quality testing.
Statistical Analysis
Baseline characteristics were expressed as mean ± standard deviation values and compared with an unpaired t test for continuous variables in normally distributed data. Data that were not normally distributed were expressed as median, 25th, and 75th percentiles and compared with nonparametric tests (Mann-Whitney rank sum test). Categorical variables were expressed as percentages and compared with the Fisher's exact test. Comparisons between the Abciximab and Eptifibatide groups were conducted by using the unpaired t test. Paired t tests were used to compare differences within the two groups before and after UFH. Analyses were performed with the SigmaStat statistical software (version 2.0; SPSS Inc., Chicago, IL) with p values <0.05 deemed significant.
RESULTS
The mean age of the study population was 61.3 ± 12.5 years. There were 18 men (62.2%). As shown in Table 1 , there were no differences in baseline characteristics between the two groups.
Inhibition of Platelet Aggregation Before UFH
The median percent inhibition of platelet aggregation achieved by eptifibatide was significantly higher compared with abciximab. This finding was evident following either ADP (96.5% [94-100] vs. 85% [77-89.5], p<0.001, Fig. 1 ) or TRAP (89.5% [84-95] vs. 59% [37.5-76.5] p<0.001; see Fig. 1 ) platelet agonism. A significantly greater percentage of patients achieved >80% inhibition of platelet aggregation with eptifibatide compared to abciximab for both ADP (100% vs. 66.7%, p=0.04) and TRAP (85.7% vs. 13.3%, p<0.001).
Inhibition of Platelet Aggregation After UFH
A greater percent inhibition of platelet aggregation was seen in eptifibatide with UFH compared with abciximab with UFH. This was evident following either ADP (95% Fig. 3 ).
However, in the abciximab group there was a significant difference between before and after UFH in percent of inhibition of platelet aggregation, for both ADP (85% [77-89.5] vs. 79% [68.8-87.5], p=0.014) and TRAP (59% [37.5-76.5] vs. 51% [34.5-71.3], p=0.04; see Fig. 3 ). Two patients in the abciximab-treated group had an extreme reduction in inhibition of platelet aggregation after addition of UFH. Abciximab-treated patients showed significant reduction in inhibition of platelet aggregation even after excluding these patients.
ACT and aPTT With Eptifibatide or Abciximab
The mean baseline aPTT in abciximab group was 26.8 ± 4.6 seconds, which increased significantly after addition of abciximabb (28.4 ± 5.4 seconds, p=0.036). In contrast, the mean baseline aPTT (27.37 ± 2.8 seconds) did not vary 
DISCUSSION
A key finding of this study is that eptifibatide achieved a higher degree of inhibition of platelet aggregation compared to abciximab using either ADP or TRAP as agonist. These results complement and extend previous reports. In a study by Kereiakes et al (7) , the degree of platelet inhibition remained durable among eptifibatide-treated patients throughout the drug infusion, but the responses in the abciximab-treated group were more variable, with about one half of patients failing to sustain >80% platelet inhibition at the end of drug infusion (7) . Similarly, in the COMPARE trial, abciximab consistently inhibited platelet aggregation early on, but there was significant recovery of platelet aggregation with the continuous infusion (13) . It has been postulated that a high free/platelet-bound drug ratio for eptifibatide (250:1) compared with abciximab (1.5:1) provides a reservoir adequate enough to inhibit newly expressed GP IIb-IIIa receptors externalized from internal platelet storage pools (14) .
Another important message from our study is that inhibition of platelet aggregation induced by abciximab, but not eptifibatide, was attenuated after administration of UFH. Using TRAP as the platelet agonist, none of the patients treated with abciximab plus UFH maintained >80% inhibition of platelet aggregation. The major effect of heparin may be to enhance platelet activation, rather than interacting directly with the GP IIb-IIIa inhibitor. Heparin has been reported to modify platelet function in vitro and in vivo, and in normal individuals as well as in patients. Experimental studies with different concentrations and sources of heparin have documented variable effects on platelet activation (15) (16) (17) (18) (19) (20) (21) (22) . In vitro, low doses of heparin are more apt to reduce platelet aggregation, while high doses are more likely to increase it (18, 19) . In unstable angina, UFH increased the percentage of activated platelets, and platelets became hyperresponsive to stimulation with ADP and TRAP (15) . Furthermore, addition of UFH to blood resulted in activation of the GP IIb-IIIa receptors, increased expression of P-selectin, increased CD62 expression, and enhanced aggregation (15, 22) . Heparin has also been shown to enhance platelet production of thromboxane A 2 (23) , which is itself a potent platelet agonist.
Clinical Significance
GPIIb-IIIa inhibitors are commonly coadministered with heparin, emphasizing the signifi-cance of the drug interaction described in this study. The importance of achieving a high level of platelet inhibition at the time of PCI has been shown in several trials. In the GOLD study, for example, the incidence of major adverse cardiac events (MACE) was significantly higher in those who did not achieve >95% inhibition of platelet aggregation 10 minutes after the bolus of GP IIIb-IIIa inhibitor (8) . In IMPACT II, patients who achieved only 30% to 50% receptor blockade were found to have modest clinical benefit at 30 days (24) . The apparent adverse effect of concomitant UFH administration on the platelet inhibition produced by abciximab may provide insight to the lack of benefit observed in the GUSTO IV-ACS trial (25) . Low molecular weight heparins may be less likely to induce platelet activation than UFH (11, 15, 26) , potentially contributing to their clinical superiority in certain clinical settings (27) .
In conclusion, eptifibatide achieves a higher degree of platelet inhibition compared to abciximab. Furthermore, the concomitant addition of unfractionated heparin significantly reduces the anti-platelet effect of abciximab but not eptifibatide. Our findings may have important clinical implications for the use of UFH in combination with GPIIb-IIIa inhibitors, especially in high-risk patients.
